241 related articles for article (PubMed ID: 33536776)
1. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Gao LH; Nie QH; Zhao XT
Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
[TBL] [Abstract][Full Text] [Related]
2. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
3. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
5. Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents.
Hong J; Wright RC; Partovi N; Yoshida EM; Hussaini T
J Clin Transl Hepatol; 2020 Sep; 8(3):322-335. PubMed ID: 33083256
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
[TBL] [Abstract][Full Text] [Related]
7. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.
Smolders EJ; Jansen AME; Ter Horst PGJ; Rockstroh J; Back DJ; Burger DM
Clin Pharmacokinet; 2019 Oct; 58(10):1237-1263. PubMed ID: 31114957
[TBL] [Abstract][Full Text] [Related]
8. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
Vermehren J; Park JS; Jacobson IM; Zeuzem S
J Hepatol; 2018 Nov; 69(5):1178-1187. PubMed ID: 30006068
[TBL] [Abstract][Full Text] [Related]
9. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Onofrio FQ; Cooper C; Borgia SM; Vachon ML; Ramji A; Lilly LB; Wong A; Booth J; Sattar I; Morales H; Lee S; Conway B; Feld JJ
Clin Infect Dis; 2021 Jun; 72(11):e799-e805. PubMed ID: 33677545
[TBL] [Abstract][Full Text] [Related]
10. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?
Bourlière M; Pietri O; Castellani P; Oules V; Adhoute X
Therap Adv Gastroenterol; 2018; 11():1756284818812358. PubMed ID: 30574189
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Heo YA; Deeks ED
Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
[TBL] [Abstract][Full Text] [Related]
15. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
16. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV
Open Forum Infect Dis; 2016 Apr; 3(2):ofw105. PubMed ID: 27419177
[TBL] [Abstract][Full Text] [Related]
18. Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.
Kaya M; Nakamura K; Sugiyama K; Kinae A; Yamaguchi H; Ukita H; Odagiri K; Ujiie C; Kato J; Kageyama F; Nagura M; Matsushita K; Sugiue K; Ishida H; Endo S; Suzuki T
J Clin Pharm Ther; 2022 Jul; 47(7):940-947. PubMed ID: 35229326
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Indolfi G; Kelly D; Nebbia G; Iorio R; Mania A; Giacomet V; Szenborn L; Shao J; Sang Yue M; Hsueh CH; Parhy B; Kersey K; Mangia A; Pawlowska M; Bansal S
Hepatology; 2022 Aug; 76(2):445-455. PubMed ID: 35112372
[TBL] [Abstract][Full Text] [Related]
20. Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
Martinez A; Khan T; Dylla DE; Marcinak J; Collins M; Saget B; Conway B
Harm Reduct J; 2023 Oct; 20(1):142. PubMed ID: 37779203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
